CLARELUX

This brand name is authorized in Austria, France, Germany, Netherlands, Poland, Spain.

Active ingredients

The drug CLARELUX contains one active pharmaceutical ingredient (API):

1	Clobetasol propionate UNII 779619577M - CLOBETASOL PROPIONATE
	Clobetasol propionate, like other topical corticosteroids, has anti-inflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.
	Read more about Clobetasol propionate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CLARELUX Cutaneous foam	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D07AD01	Clobetasol	D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07A Corticosteroids, plain → D07AD Corticosteroids, very potent (group IV)
Discover more medicines within D07AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	01010495, 17522300, 17631101, 17921891
ES	Centro de información online de medicamentos de la AEMPS	66071
FR	Base de données publique des médicaments	60021312, 63339576
NL	Z-Index G-Standaard, PRK	80861
PL	Rejestru Produktów Leczniczych	100232658